Introduction: Most common benign breast conditions presenting in the breast clinics include fibroadenomas and mastalgia, both these conditions cause considerable anxiety in the patients. Among other treatment modalities, the hormonal drug treatments are gaining popularity. Ormeloxifene (centchroman) is an antiestrogenic drug which is shown to have effect in reducing the pain in mastalgia patients and the size of fibroadenoma. Objectives: Ormeloxifene is selective antiestrogen and a nonsteroidal drug. It has a discerning antiestrogen action and hence is useful for the treatment of mastalgia and multiple small fibroadenomas. Hence, the objective of our study was to assess the effect of Ormeloxifene (centchroman) on multiple fibroadenoma and mastalgia. Materials and Methods: Patients with benign breast disease attending our surgery outpatient department from June 2016 to July 2017. Patients were started on Ormeloxifene 30 mg on alternate days for a period of 3 months. Patients were followed up to 6 months after the inception of the study. Parameters recorded include the Visual Analog Scale (VAS) for pain and ultrasonography for breast lump size. Results: Thirty patients were included in the study. We found very good response in the mastalgia; the VAS scores in these patients dropped from 10 to 3 in 90% in the 1st week of introduction of the drug, and at the end of 1 month, almost all of the patients were painless. Overall final response was noted in terms of complete dissolution and change in the size was noted in 34% partial response in 46 %, no changes in 17 % and increase in size of fibroadenoma was noted in only one case. Conclusion: Novex is proved to be safe drug for the treatment of mastalgia and fibroadenoma. Its results were great in mastalgia group. At the end of 6 months, the number of surgeries (if needed) decrease and there is considerable improvement in the patient satisfaction rate.
Background: Breast tuberculosis is a rare extra pulmonary tuberculosis presentation usually misdiagnosed as carcinoma, pyogenic abscess or idiopathic granulomatous mastitis. Detection of tubercular bacilli by ZN stain, culture and CBNAAT along with caseating granuloma on histopathology helps in diagnosis. Aims and Objectives: To study the clinico-pathological characteristic of breast tuberculosis and diagnostic accuracy of CBNAAT for early and specific diagnosis in reference to histopathological test Material and Methods: 38 cases of BTB between August2012 to July 2017 were studied. Culture for acid-fast bacilli, smear positivity on Z-N staining, CBNAAT, and cytological and histological examination was done for confirmation. Results: Prevalence of BTB in this study was found to be 3.95% .The risk factors were reproductive age (20-35), multiparity, lactation and low socioeconomic status. Unilateral lump in the upper outer and central quadrant of the breast was the commonest observation. Only 34.2% were diagnosed provisionally as BTB rest 73.68% were misdiagnosed as fibroadenoma, breast abscess and malignancy Clinically nodulo-caseous variety(55.6 %) disseminated (18.4%) and tubercular abscess (26.3%) were seen. Sensitivity of ZN staining, culture, FNAC and histopathology is 15.8%,5.8%, 74% ,100%respectively. Sensitivity, specificity, positive predictive value, and negative predictive value for the CBNAAT test were 81.818%, 93.103%, 93.10%, and 81.82% respectively.39.4% were cured completely with ATT with 60.52% with residual lesions needed surgery Conclusion: This study highlights the importance of early diagnosis and aggressive medical and if required surgical management to cure this disease. CBNAAT should be used as an additional test to conventional smear microscopy, culture, FNAC and histology. Keywords: Breast tuberculosis, CBNAAT, Extrapulmonary tuberculosis, breast lump
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.